REFERENSI

1. Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among
foreign-born persons living in the United States by country of origin. Hepatol. 2012;56:422-33.
2. Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis.
2005;9:191-211.
3. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut.
1996;38(Suppl 2):S18-23.
4. World Health Organization. Hepatitis B. World Health Organization Fact Sheet No 204, 2014.
Available at http://www.who.int/mediacentre /fact sheets/fs204/en/.
5. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging
prevention and control measures. J Viral Hepat. 2004;11:97-107.
6. Lok AS. Chronic hepatitis B. N Engl J Med. 2002;346:1682-3.
7. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to
estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34:1329-39.
8. Gish RG, Locarnini SA. Chronic hepatitis B: Current testing strategies. Clin Gastroenterol Hepatol.
2006;4:666-76.
9. Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatol.
2009;49:S166-73.
10. Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B
surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods.
2004;115:217-22.
11. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M. Early serum
HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in
HBeAg-negative patients. Hepatol. 2009;49:1151-7.
12. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, et al. Kinetics of hepatitis B surface
antigen decline during 3 years of telbivudine treatment in hepatitis B antigen-positive patients.
Hepatol. 2010;52:1611-20.
13. Chan HL, Wong VW, Tse AM, Tse C, Chim AM, Chan H, et al. Serum hepatitis B surface antigen
quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin
Gastroenterol Hepatol. 2007;5:1462-8.
14. Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP. Lack of correlation
between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc:
Implications for future HBV screening policy. Transfus. 2004;44:1332-9.
15. Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, et al. Quantitative detection of
hepatitis B surface antigen by chemiluminiscent microparticle immunoassay during lamivudine
treatment. J Med Virol. 2005;75:235-9.
16. Ozaras R, Tabak F, Tahan V, Ozturk R, Akin H, Mert A, et al. Correlation of quantitative assay of
HBsAg and HBV DNA levels during chronic HBV treatment. Dig Dis Sci. 2008;53:2995-8.
17. Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV
genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol.
2002;17:165-70.
18. Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatol.
2009;49:S166-73.
19. Ozdil B, Cosar AM, Akkiz H, Sandikci MU, Kece C. Negative correlation between viral load and
HBsAg levels in chronic HBV-infected patients. Arch Virol. 2009;154:1451-5.
20. Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, et al. Quantitative detection of
hepatitis B surface antigen by chemiluminiscent microparticle immunoassay during lamivudine
treatment. J Med Virol. 2005;75:235-9.
21. Ozaras R, Tabak F, Tahan V, Ozturk R, Akin H, Mert A, et al. Correlation of quantitative assay of
HBsAg and HBV DNA levels during chronic HBV treatment. Dig Dis Sci. 2008;53:2995-8.
22. Sonneveld MJ, Zoutendijk R, Janssen HL. Hepatitis B surface antigen monitoring and management of
chronic hepatitis B. J Viral Hepat. 2011;18:449-57.
23. Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP. Lack of correlation
between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc:
Implications for future HBV screening policy. Transfus. 2004;44:1332-9.